

NOV 30 2007

400 Garden City Plaza - Suite 300  
Garden City, New York 11530  
(516) 742-4343 - Telephone  
(516) 742-4366 - Facsimile  
e-mail: intprop@ssmp.com

**SCULLY, SCOTT, MURPHY  
& PRESSER, P.C.**

# Fax

**To:** Examiner Kendra D. Carter  
Group Art Unit: 1617  
Confirmation No.: 5994

**From:** Xiaochun Zhu, Ph.D.

**Fax:** 571-273-8300

**Pages:** 8 (including cover)

**Phone:**

**Date:** November 30, 2007

**Re:** Michael Xilinas, et al.  
U.S. Patent Application No. 10/717,182  
Filed: November 18, 2003  
Docket: 18381A

**CC:**

☐ Urgent    ☒ For Review    ☐ Please Comment    ☐ Please Reply    ☐ Please Recycle

**The following is attached hereto:**

1. General Transmittal (in duplicate);
2. Response Under 37 C.F.R. §§1.111 & 1.143;
3. Certificate of Facsimile.

If you have any problems concerning this facsimile, please call (516) 742-4343 and for Elyssa Hudes.

**CONFIDENTIALITY:** The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right or publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.

NOV 30 2007

**CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)**

Applicant(s): Michael XILINAS, et al.

Docket No.

18381A

Application No.

10/717,182

Filing Date

November 18, 2003

Examiner

Kendra D. Carter

Group Art Unit

1617


Invention: USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

I hereby certify that this

RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143*(Identify type of correspondence)*Is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. (571) 273-8300)on November 30, 2007*(Date)*Xiaochun Zhu*(Typed or Printed Name of Person Signing Certificate)*  
*(Signature)*

Note: Each paper must have its own certificate of mailing.

NOV 30 2007

<b>TRANSMITTAL LETTER</b> (General - Patent Pending)				Docket No. <b>18381A</b>					
In Re Application Of: <b>Michael XILINAS, et al.</b>									
Application No. <b>10/717,182</b>	Filing Date <b>November 18, 2003</b>	Examiner <b>Kendra D. Carter</b>	Customer No. <b>23389</b>	Group Art Unit <b>1617</b>	Confirmation No. <b>5994</b>				
Title: <b>USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE</b>									
<u>COMMISSIONER FOR PATENTS:</u>									
Transmitted herewith is:  <b>RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143</b>									
In the above identified application.									
<input checked="" type="checkbox"/> No additional fee is required. <input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <b>19-1013/SSMP</b> as described below. <input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input type="checkbox"/> Charge any additional fee required. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.									
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>									
 _____ Xiaochun Zhu Reg. No. 56,311 SCULLY, SCOTT, MURPHY & PRESSER, P.C.			Dated: November 30, 2007						
TG/XZ:eh  cc:			<table border="1" style="width: 100%; border-collapse: collapse;"><tr><td style="padding: 5px;">I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460" [37 CFR 1.8(a)] on _____</td></tr><tr><td style="padding: 5px;">(Date)</td></tr><tr><td style="padding: 5px;">_____ Signature of Person Mailing Correspondence</td></tr><tr><td style="padding: 5px;">_____ Typed or Printed Name of Person Mailing Correspondence</td></tr></table>			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460" [37 CFR 1.8(a)] on _____	(Date)	_____ Signature of Person Mailing Correspondence	_____ Typed or Printed Name of Person Mailing Correspondence
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460" [37 CFR 1.8(a)] on _____									
(Date)									
_____ Signature of Person Mailing Correspondence									
_____ Typed or Printed Name of Person Mailing Correspondence									

P16A/REV04

PAGE 4/8 \* RCVD AT 11/30/2007 9:38:23 AM [Eastern Standard Time] \* SVR:USPTO-EFXRF-3/3 \* DNIS:2738300 \* CSID:5167424366 \* DURATION (mm-ss):03-50

RECEIVED  
CENTRAL FAX CENTER

NOV 30 2007

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Michel Xilinas, et al.	<b>Examiner:</b>	Kendra D. Carter
<b>Serial No:</b>	10/717,182	<b>Art Unit:</b>	1617
<b>Filed:</b>	November 18, 2003	<b>Docket:</b>	18381A
<b>For:</b>	USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE	<b>Dated:</b>	November 30, 2007


**Confirmation No.:** 5994Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450**RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143**

Sir:

In response to the Office Action dated November 5, 2007, setting forth a requirement for restriction, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, Applicants provisionally elect, with traverse, the subject matter of Group I, claims 6, 13 and 42-63 drawn to a pharmaceutical composition, for continued prosecution.

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to (571) 273-8300 at the Patent and Trademark Office on the date shown below.

Dated: November 30, 2007  
Xiaochun Zhu